Emerging treatment options for MZL
Catherine Thieblemont, MD, PhD, Saint-Louis University Hospital, Paris, France, discusses the evolving treatment landscape of marginal zone lymphoma (MZL), commenting on the efficacy and tolerability of emerging agents such as BTK inhibitors, PI3-Kinase inhibitors, CAR-T therapy, and bispecific antibodies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.